AEMD (Aethlon Medical) ROCE %: -121.38% (As of Mar. 2026)


AEMD Aethlon Medical Inc AEMD
23 GF Score
Price $1.22
! 1 Warning Sign
View Full Analysis

What is Aethlon Medical ROCE %?

Aethlon Medical AEMD -10.29% 23 ROCE % is -121.38% as of Mar. 2026. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aethlon Medical's annualized ROCE % for the quarter that ended in Mar. 2026 was -121.38%.

Aethlon Medical  (NAS:AEMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aethlon Medical ROCE % Related Terms

Aethlon Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Aethlon Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aethlon Medical ROCE % Chart

Aethlon Medical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.51 -70.83 -112.73 -225.28 -137.95

Aethlon Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -473.25 -156.85 -125.87 -129.71 -121.38
AEMD
23GF Score
Aethlon Medical Inc AEMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aethlon Medical ROCE % Calculation

Aethlon Medical's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-7.137/( ( (7.36 - 1.899) + (6.333 - 1.447) )/ 2 )
=-7.137/( (5.461+4.886)/ 2 )
=-7.137/5.1735
=-137.95 %

Aethlon Medical's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7.092/( ( (8.057 - 1.257) + (6.333 - 1.447) )/ 2 )
=-7.092/( ( 6.8 + 4.886 )/ 2 )
=-7.092/5.843
=-121.38 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -121.38% mean?
Aethlon Medical (AEMD) has a ROCE % of -121.38% as of Mar. 2026.
Is Aethlon Medical's ROCE % too high?
Aethlon Medical's current ROCE % is -121.38%. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's ROCE % compare to RMSL and BTCY?
Aethlon Medical's ROCE % of -121.38% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current ROCE % is -121.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current ROCE % of -121.38%. The current ROCE % is -121.38%. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current ROCE % is -121.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aethlon Medical Business Description

Address 11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score

Get the complete analysis for AEMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.22
Price